Table 1.

Patient characteristics of groups with and without cLVH at PD initiation in all patients (N = 131)

Variables	Total	cLVH(−)	cLVH(+)	p value
	(N = 131)	(N = 102)	(N = 29)
Age (years)	60.8 ± 12.7	58.2 ± 11.8	70.1 ± 11.2	< 0.001
Male gender (n [%])	97 [74%]	80 [78%]	17 [59%]	0.032
Diabetes (n [%])	44 [34%]	34 [33%]	10 [34%]	0.909
CVD before PD initiation	25 [19%]	16 [16%]	9 [31%]	0.064
(n [%])
Automated PD (n [%])	117 [89%]	93 [92%]	24 [83%]	0.198
RAS inhibitor (n [%])	111 [85%]	90 [88%]	21 [72%]	0.037
Beta-blocker (n [%])	16 [12%]	11 [11%]	5 [17%]	0.347
Anti-platelet agent (n [%])	39 [30%]	27 [26%]	12 [41%]	0.166
Body mass index (kg/m2)	22.2 ± 3.6	22.4 ± 3.4	21.4 ± 3.9	0.177
Systolic blood pressure (mmHg)	132 ± 18	131 ± 18	138 ± 18	0.079
Diastolic blood pressure (mmHg)	77 ± 12	78 ± 12	72 ± 11	0.036
Pulse pressure (mmHg)	56 ± 15	53 ± 13	65 ± 18	< 0.001
Urine volume (ml/day)	1100 [760, 1575]	1200 [800, 1538]	1050 [650, 1600]	0.241
Hemoglobin (g/dl)	11.0 ± 1.1	11.1 ± 1.0	10.4 ± 1.1	0.002
Albumin (g/dl)	3.6 ± 0.4	3.7 ± 0.4	3.2 ± 0.5	< 0.001
Blood urea nitrogen (mg/dl)	52.4 ± 13.2	53.0 ± 12.7	50.5 ± 14.8	0.381
Creatinine (mg/dl)	6.8 ± 2.4	7.2 ± 2.4	5.7 ± 2.1	0.004
Corrected calcium (mg/dl)	9.0 ± 0.7	9.0 ± 0.6	9.1 ± 0.8	0.448
Phosphate (mg/dl)	4.8 ± 1.1	4.8 ± 1.1	4.5 ± 1.1	0.185
iPTH (pg/ml)	207 [137, 362]	211 [149, 381]	150 [79, 215]	0.002
Log CRP	−0.86 ± 0.58	−0.95 ± 0.56	−0.55 ± 0.54	< 0.001
Total cholesterol (mg/dl)	197 ± 41	198 ± 41	196 ± 41	0.824
Triglyceride (mg/dl)	144 [100, 185]	148 [106, 187]	109 [81, 166]	0.039
Renal weekly Kt/V	1.17 ± 0.61	1.19 ± 0.61	1.12 ± 0.61	0.601
Total weekly Kt/V	2.23 ± 0.58	2.24 ± 0.58	2.17 ± 0.57	0.543
D/Pcre	0.58 ± 0.11	0.57 ± 0.10	0.62 ± 0.12	0.022
LVMI (g/m2)	99.1 [81.2, 121.6]	91.4 [77.3, 107.4]	135.0 [123.1, 162.6]	< 0.001
RWT	0.43 [0.38, 0.51]	0.40 [0.36, 0.48]	0.51 [0.46, 0.62]	< 0.001

Values are expressed as mean ± standard deviation, median [interquartile range] or number [percentage]